Teladoc director files initial Form 3

Teladoc Health, Inc. director Susan R. Salka filed an initial Form 3 ownership report.

Accepted by SEC EDGAR 04/01/2026 - 04:04 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Teladoc Health, Inc. director Susan R. Salka filed an initial Form 3 ownership report. The filing lists her as a director but shows no reportable share transactions or derivative positions, serving mainly as a baseline disclosure of insider status and potential future reporting obligations.

Key Terms

Form 3, reporting person, derivative securities

3 terms

Form 3 regulatory

"filed an initial Form 3 ownership report"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

reporting person regulatory

"when an insider first becomes a reporting person"

derivative securities financial

"The filing shows no derivative securities for Susan R. Salka"

Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Teladoc (TDOC) Form 3 filing for Susan R. Salka mean?

The Form 3 for Susan R. Salka at Teladoc Health records her status as a director and establishes an initial insider ownership baseline. It does not show any share purchases, sales, or derivative positions, but signals she will report future insider transactions on Forms 4 or 5.

Did Teladoc (TDOC) director Susan R. Salka buy or sell shares in this Form 3?

No, the Form 3 for Susan R. Salka reports no share purchases, sales, or derivative transactions. It simply identifies her as a director and sets up her insider reporting profile, without disclosing any current holdings or recent trading activity in Teladoc Health stock.

Does the Teladoc (TDOC) Form 3 show any derivative securities for Susan R. Salka?

The filing shows no derivative securities for Susan R. Salka. The derivative summary is empty and transaction counts are zero, indicating there are no reportable options, warrants, or similar instruments associated with her at the time of this initial ownership report.

Is the Susan R. Salka Form 3 for Teladoc (TDOC) a trading signal?

The Form 3 itself is not a trading signal. It is an administrative filing that identifies Susan R. Salka as a Teladoc director and establishes her as a Section 16 reporting person, without revealing any insider trading or specific ownership amounts in this disclosure.

Why are there no transactions listed in the Teladoc (TDOC) Form 3 for Susan R. Salka?

Form 3 often contains only baseline information when an insider first becomes a reporting person. In this case, all transaction counts are zero, so the filing simply registers Susan R. Salka’s director role at Teladoc without documenting any historical trades or derivative holdings.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

SALKA SUSAN R

(Last) (First) (Middle)

C/O TELADOC HEALTH, INC.,

155 E 44TH ST, SUITE 1700

(Street)

NEW YORK NEW YORK 10017

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/30/2026

3. Issuer Name and Ticker or Trading Symbol
Teladoc Health, Inc. [ TDOC ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit 24 -- Power of Attorney

No securities are beneficially owned.

	/s/ Adam C. Vandervoort, Attorney-in-Fact	04/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)